Trogarzo® is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. Trogarzo® belongs to the CD4-directed post-attachment HIV-1 inhibitor class of antiretrovirals. In the United States, Trogarzo® is approved, in combination with other antiretroviral(s), for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant (MDR) HIV-1 infection failing their current antiretroviral regimen. Trogarzo® has been approved in the US since March 2018 and was the first intravenous agent approved for the treatment of HIV-1 infection. In October 2022, the FDA approved an IV push method of administration of Trogarzo®. The Company is also investigating an intramuscular method of administration of Trogarzo®.

It is estimated that there are between 30,000 and 35,000 people living with MDR HIV-1 in the United States.

For full prescribing information and safety information about Trogarzo®, please visit: